Sirolimus
"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
Descriptor ID |
D020123
|
MeSH Number(s) |
D02.540.505.760
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 1 | 1 | 1999 | 1 | 1 | 2 | 2000 | 4 | 1 | 5 | 2001 | 1 | 1 | 2 | 2003 | 3 | 2 | 5 | 2004 | 3 | 7 | 10 | 2005 | 2 | 3 | 5 | 2006 | 2 | 1 | 3 | 2007 | 2 | 3 | 5 | 2008 | 2 | 3 | 5 | 2009 | 3 | 2 | 5 | 2010 | 10 | 4 | 14 | 2011 | 6 | 7 | 13 | 2012 | 6 | 0 | 6 | 2013 | 9 | 7 | 16 | 2014 | 8 | 6 | 14 | 2015 | 1 | 2 | 3 | 2016 | 6 | 4 | 10 | 2017 | 1 | 0 | 1 | 2018 | 2 | 3 | 5 | 2019 | 3 | 1 | 4 | 2020 | 1 | 5 | 6 | 2021 | 0 | 4 | 4 | 2022 | 0 | 2 | 2 | 2023 | 1 | 2 | 3 | 2024 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
Yamaguchi S, Sedaka R, Kapadia C, Huang J, Hsu JS, Berryhill TF, Wilson L, Barnes S, Lovelady C, Oduk Y, Williams RM, Jaimes EA, Heller DA, Saigusa T. Rapamycin-encapsulated nanoparticle delivery in polycystic kidney disease mice. Sci Rep. 2024 07 02; 14(1):15140.
-
Gupta AA, Xue W, Harrison DJ, Hawkins DS, Dasgupta R, Wolden S, Shulkin B, Qumseya A, Routh JC, MacDonald T, Feinberg S, Crompton B, Rudzinski ER, Arnold M, Venkatramani R. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Lancet Oncol. 2024 Jul; 25(7):912-921.
-
Brown JA, Faley SL, Judge M, Ward P, Ihrie RA, Carson R, Armstrong L, Sahin M, Wikswo JP, Ess KC, Neely MD. Rescue of impaired blood-brain barrier in tuberous sclerosis complex patient derived neurovascular unit. J Neurodev Disord. 2024 May 23; 16(1):27.
-
Borst AJ, Eng W, Griffin M, Ricci KW, Engel E, Adams DM, Dayneka J, Cohen-Cutler SJ, Andreoli SM, Wu MD, Wheeler AP, Heym KM, Crary SE, Nakano TA, Schulte RR, Setty BA, McLean TW, Pahl KS, Intzes S, Pateva I, Teitelbaum M, Zong Z, Li Y, Jeng MR. Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study. Pediatr Blood Cancer. 2024 Mar; 71(3):e30779.
-
Shorofsky MJ, Morgan GJ, Mejia E, Rodriguez SA, Greene M, Sheaks P, Ivy D, Zablah JE. Management of Complex Pulmonary Vein Stenosis at Altitude Combining Comprehensive Percutaneous Interventional Treatment with Sirolimus, Pulmonary Hypertension Medications and Intraluminal Imaging with Optical Coherence Tomography. Pediatr Cardiol. 2023 Jun; 44(5):1125-1134.
-
Gupta N, Zhang B, Zhou Y, McCormack FX, Ingledue R, Robbins N, Kopras EJ, McMahan S, Singla A, Swigris J, Cole AG, Holz MK. Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis. Chest. 2023 05; 163(5):1144-1155.
-
Elgendy TY, Waldner M, Zhang W, Kim DY, Minervini MI, Komatsu C, Kulahci Y, Washington KM, Gorantla VS, Ezzelarab MB, Solari MG, Thomson AW. Tacrolimus before CTLA4Ig and rapamycin promotes vascularized composite allograft survival in MGH miniature swine. Transpl Immunol. 2022 12; 75:101696.
-
Freeman CL, Pararajalingam P, Jin L, Balasubramanian S, Jiang A, Xu W, Grau M, Zapukhlyak M, Boyle M, Hodkinson B, Schaffer M, Enny C, Deshpande S, Sun S, Vermeulen J, Morin RD, Scott DW, Lenz G. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial. Leukemia. 2022 10; 36(10):2479-2487.
-
Major A, Kline J, Karrison TG, Fishkin PAS, Kimball AS, Petrich AM, Nattam S, Rao K, Sleckman BG, Cohen K, Besien KV, Rapoport AP, Smith SM. Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 07 01; 107(7):1608-1618.
-
Petrache I, de Boer E. Rapalogs Target the Endothelium to Set the Stage for Acute Lung Injury. Am J Respir Cell Mol Biol. 2021 12; 65(6):576-577.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|